Compare REKR & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REKR | ONCY |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Pharmaceuticals and Biotechnology |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.5M | 94.0M |
| IPO Year | N/A | 1999 |
| Metric | REKR | ONCY |
|---|---|---|
| Price | $1.45 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 2.6M | 1.0M |
| Earning Date | 11-13-2025 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $49,028,000.00 | N/A |
| Revenue This Year | $11.82 | N/A |
| Revenue Next Year | $22.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.89 | N/A |
| 52 Week Low | $0.62 | $0.33 |
| 52 Week High | $3.42 | $1.51 |
| Indicator | REKR | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 69.09 |
| Support Level | $1.33 | $0.98 |
| Resistance Level | $1.79 | $1.08 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 25.27 | 89.74 |
Rekor Systems Inc is a United States-based company. The company is engaged in providing real-time roadway intelligence through AI-driven decisions. The firm uses artificial intelligence to analyze video streams and transform them into AI-driven decisions. The company's technology and machine learning models power all solutions, including Rekor Command for transportation management, Rekor Discover for urban mobility, and Rekor Scout for public safety, and commercial use. Its geographical segments are the United States and Others, of which a majority of its revenue comes from the United States.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.